Acacia Research Corporation (Nasdaq: ACTG) announced today that a
subsidiary has acquired 7 medtech patent portfolios comprised of over
150 patents and pending applications relating to medical devices,
biologics and diagnostic techniques.
"Acacia continues to increase the number of patent portfolios we control
in the medical technology and life sciences sector," states Paul Ryan,
CEO and President. "We are rapidly expanding our presence as a leader in
patent licensing in the medical device, diagnostics and life sciences
sectors."
New research explores how antimicrobial exposure affects Parkinson’s disease risk